1.
A Delluc, E Pasquier, L de Saint Martin, D Mottier. Rituximab’s cost for the treatment of primary cold agglutinin disease should not limit its use. Haematologica 2006;91(3):ECR05-ECR05; https://doi.org/10.3324/%x.